NDAORALCAPSULEPriority Review
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
LYNPARZA (olaparib) by AstraZeneca is poly(adp-ribose) polymerase inhibitors [moa]. First approved in 2014.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYNPARZA (olaparib) is an oral small-molecule poly(ADP-ribose) polymerase (PARP) inhibitor that blocks DNA repair mechanisms in cancer cells, particularly those with BRCA mutations or homologous recombination deficiency. It is indicated across multiple oncology settings including ovarian, breast, pancreatic, and prostate cancers. The drug works by trapping PARP enzymes on DNA, leading to tumor cell death in genetically susceptible populations.
$0.487BPart D
PeakStable
4.7 years to LOELYNPARZA is at peak commercial maturity with sustained Part D spending; sales teams are likely mature and focused on indication expansion and patient retention rather than primary launch activities.
Mechanism of Action
Poly(ADP-Ribose) Polymerase Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
PROLONG (PRostateOLaparibONcombinationGcc) Study
Started Jun 2026
75 enrolled
Metastatic Castration-resistant Prostate Cancer (mCRPC)
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer
Started Jun 2026
35 enrolled
Ovary Cancer
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
Started Dec 2025
50 enrolled
Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
Started Sep 2025
50 enrolled
Endometrial Cancer
Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
Started Aug 2025
33 enrolled
High Grade Serous Ovarian Cancer
Worked on LYNPARZA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.